Xeljanz beats placebo in Phase III psoriatic arthritis trial

Pfizer Inc. (NYSE:PFE) said 5 and 10 mg twice-daily Xeljanz tofacitinib met the co-primary endpoints of superiority to placebo at three

Read the full 217 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE